Ligand Pharmaceuticals Inc. (Nasdaq: LGND) partner Amgen Inc. (Nasdaq: AMGN) reported disappointing results from a Phase 3 trial of Kyprolis. Shares of Ligand Pharmaceuticals plummeted $13.45 to close at $99.64 while Amgen stock dropped $1.90 to close at $171.63.
Disappointing study results for Ligand and Amgen
September 27, 2016 at 19:02 PM EDT